Today marks an important milestone at Novo Nordisk Pharmatech as we announce the launch of TrypsiNNex® – a new recombinant enzyme in the company portfolio. This product represents a key part of our growth strategy in the specialty enzymes sector for pharmaceutical manufacturing. TrypsiNNex® is a sustainable, animal-free trypsin product
Safety Data Sheets SDS for TrypsiNNex Resources Download the Safety Data Sheet (SDS) for TrypsiNNex®, our recombinant porcine trypsin, using the relevant link below. This sheet is designed following the UN’s Globally Harmonized System (GHS) for chemical classification and labeling. The SDS provides important safety information, covering everything from safe handling tips
Dive into our collection of application notes and educational material about our recombinant animal-free trypsin TrypsiNNex®.
We are thrilled to announce our attendance at the upcoming BioProcess International Congress, which will take place September 24-26 at Hynes Convention Center in Boston! We will showcase one of our key specialities, Recombinant Insulin, at booth 814. Approved by the FDA and EMA, our animal-free Insulin is a vital
In order to meet significantly higher demand from Novo Nordisk A/S for raw materials for the production of medicines to fight chronic diseases, Novo Nordisk Pharmatech A/S is building a new factory at Ådalen 16 in Køge. In March 2023, Novo Nordisk Pharmatech announced the purchase of a 47,000 m²
Cell culture remains one of the most important bioprocessing tools we have today
Københavnsvej 216
4600 Køge,
Denmark
+45 5667 1000
[email protected]
CVR-no. 13246149
